SCHEMBL5734397

SCHEMBL5734397

CCOP(=O)(O)CC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.50
FEN1 P39748 1/20 0.50
CETP P11597 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MMP2 P08253 1/20 0.47
CA9 Q16790 1/20 0.47
MMP1 P03956 2/20 0.47
HDAC3 O15379 1/20 0.46
POLB P06746 2/20 0.45
LMNA P02545 1/20 0.45
PARP10 Q53GL7 1/20 0.45
SRD5A2 P31213 3/20 0.44
LTA4H P09960 1/20 0.44
HPGD P15428 2/20 0.43
NPC1 O15118 1/20 0.43
CRHBP P24387 1/20 0.43
RAB9A P51151 1/20 0.43
CRHR2 Q13324 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734845 0.88 POLB (0.57) CETPPOLBLMNAHPGDNPC1
SCHEMBL5733094 0.88 ERCC5 (0.53) ERCC5FEN1CETPPOLBLMNA
SCHEMBL28005057 0.86 POLB (0.56) CETPPOLBLMNAHPGDNPC1
SCHEMBL5733605 0.80 NPC1 (0.51) CETPHDAC3POLBHPGDNPC1
SCHEMBL2322449 0.79 HTR7 (0.47) HDAC3POLBLMNAHPGDNPC1
SCHEMBL5734390 0.78 POLB (0.57) ERCC5FEN1CA12CA1CA2
SCHEMBL4943383 0.77 GCK (0.44) ERCC5FEN1CETPPOLBLMNA
SCHEMBL1269735 0.76 ERCC5 (0.64) ERCC5FEN1MMP1HDAC3POLB
SCHEMBL5733422 0.76 RAB9A (0.51) POLBLMNAHPGDNPC1RAB9A
SCHEMBL5732673 0.76 CES2 (0.51) HDAC3POLBHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 ERCC5 3838/4885FEN1 3737/4885CETP 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.